Medikamentös-induzierter Tremor

Zusammenfassung

Der medikamentös-induzierte Tremor stellt eine wichtige Differenzialdiagnose von Tremorerkrankungen dar. Vor dem Hintergrund einer zunehmenden Polypharmazie und einer ständig älter werdenden Bevölkerung kann die Kenntnis von potenziell tremorauslösenden Medikamenten helfen, ein Risikoprofil für den einzelnen Patienten zu erstellen. Der medikamentös-induzierte Tremor tritt als häufige Nebenwirkung antipsychotischer Therapien auf, aber auch als Reaktion auf zahlreiche andere Medikamente wie Antidepressiva, Sympathomimetika, Antiarrhythmika oder Antiepileptika. Der vorliegende Artikel stellt neben einer Synopsis der häufigsten tremorauslösenden Medikamente Strategien dar, die eine Behandlung durch Austausch des auslösenden Medikamentes oder eine symptomatische Therapie ermöglichen.

Abstract

Drug-induced tremor is an important differential diagnosis for tremor syndromes. In view of a constantly ageing population and increasingly frequent polypharmacotherapy, identification of potentially tremor-inducing drugs may help generating risk profiles for individual patients. Drug-induced tremor has often been seen as a complication of antipsychotic therapy, but its occurrence has also been described in response to a great diversity of compounds such as antidepressants, sympathomimetics, antiarrhythmics, antiepileptics and other drugs. The present article presents a synopsis of the most prevalent tremor-inducing drugs as well as strategies to overcome drug-induced tremor, either by replacement of the causative drug or by symptomatic therapies.

Schlüsselwörter

Neuroleptika - Antiepileptika - Betamimetika

Keywords

neuroleptics - antiepileptics - betamimetics

Literatur

• 1 Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring – cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.  Pharmacoepidemiol Drug Saf. 1997;  6 (Suppl 3) 71-77
• 2 Roughead E E, Gilbert A L, Primrose J G et al. Drug-related hospital admissions: a review of Australian studies published 1988 – 1996.  Med J Aust. 1998;  165 405-408
• 3 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalised patients. A meta-analysis of prospective studies.  JAMA. 1998;  279 1200-1205
• 4 Pouyanne P, Haramburu F, Imbs J L et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study.  BMJ. 2000;  320 1036
• 5 Bates D W, Spell N, Cullen D J et al. The costs of adverse drug events in hospitalized patients.  JAMA. 1997;  277 307-311
• 6 Classen D C, Pestonik S L, Evans R S et al. Adverse drug events in hospitalised patients: excess length of stay, extra costs and attributable mortality.  JAMA. 1997;  277 301-306
• 7 Schneeweis S, Hasford J, Göttler M et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study.  Eur J Clin Pharmacol. 2002;  58 285-291
• 8 Dafotakis M, Schönfeldt-Lecuona C, Fink G R et al. Psychogenic tremor.  Fortschr Neurol Psychiatr. 2008;  76 647-654
• 9 Charness M E, Morady F, Scheinman M M. Frequent neurologic toxicity associated with amiodarone therapy.  Neurology. 1984;  34 669-671
• 10 Harris L, McKenna W J, Rowland E. Side effects and possible contraindications of amiodarone use.  Am Heart J. 1983;  106 916-923
• 11 Hilleman D, Miller M A, Parker R et al. Optimal management of amiodarone therapy: efficacy and side effects.  Pharmacotherapy. 1998;  18 138S-145S
• 12 Werner E G, Olanow C W. Parkinsonism and amiodarone therapy.  Ann Neurol. 1989;  25 630-632
• 13 Arnaud A, Neau J P, Rivasseau-Jonveaux T et al. Neurological toxicity of amiodarone. 5 case reports.  Rev Med Interne. 1992;  13 419-422
• 14 Palakurthy P R, Iyer V, Meckler R J. Unusual neurotoxicity associated with amiodarone therapy.  Arch Intern Med. 1987;  147 881-884
• 15 Raethjen J, Lemke M R, Lindemann M et al. Amitriptyline enhances the central component of physiological tremor.  J Neurol Neurosurg Psychiatry. 2001;  70 78-82
• 16 Capponi R, Hhhormazabal L, Schmid-Burgk W. Dicofensine and imipramine. A double-blind comparative trial in depressive out-patients.  Neuropsychobiology. 1985;  14 173-180
• 17 Ackerman D L, Greenland S, Bystritsky A et al. Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder.  J Clin Psychopharmacol. 1996;  16 324-328
• 18 Smith W T, Glaudin V, Panagides J et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.  Psychopharmcol Bull. 1990;  26 191-196
• 19 Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.  J Clin Psychiatr. 1985;  46 32-37
• 20 Lepine J P, Goger J, Blashko C et al. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression.  Int Clin Psychopharmacol. 2000;  15 263-271
• 21 Diaz-Martinez A, Benassinni O, Ontiveros A et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.  Clin Ther. 1998;  20 467-476
• 22 Milne R J, Goa K L. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.  Drugs. 1991;  41 450-477
• 23 Skop B P, Finkelstein J A, Mareth T R et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease.  Am J Emerg Med. 1994;  12 642-644
• 24 Chouinard G, Saxena B, Belanger M C et al. A canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.  J Affect Disord. 1999;  54 39-48
• 25 Guelfe J D, Dreyfus J F, Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine.  Br J Clin Pharmacol. 1983;  15 (Suppl 3) 411-417
• 26 Larsen J K, Holm P, Hoyer E et al. Moclobemide and clomipramine in reactive depression. A placebo-controlled randomised clinical trial.  Acta Psychiatr Scand. 1989;  79 530-536
• 27 Koczkas C, Holm P, Karlsson A. Moclobemide and clomipramine in endogenous depression. A randomised clinical trial.  Acta Psychiatr Scand. 1989;  79 523-529
• 28 Borys D J, Setzer S C, Ling L J et al. Acute fluoxetine overdose: a report of 234 cases.  Am J Emerg Med. 1992;  10 115-120
• 29 Francois B, Marquet P, Desachy A et al. Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association.  Intensive Care Med. 1997;  23 122-124
• 30 Kronfol Z, Greden J F, Zis A P. Imipramine-induced tremor: effects of a beta-adrenergic blocking agent.  J Clin Pschiatry. 1983;  44 225-226
• 31 Watson J U, Beaumont G, Poole P. Clomipramine and age: an interaction study.  J Int Med Res. 1980;  8 81-84
• 32 Larsen K, Schmekel B. Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets.  Eur J Clin Pharmacol. 1993;  45 303-305
• 33 Faulds D, Hollingshead L M, Goa K L. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.  Drugs. 1991;  42 115-137
• 34 Schaffler K, Reeh P W. Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol.  Int J Clin Pharmacol Ther Toxicol. 1987;  25 673-682
• 35 Billing B, Dahlqvist R, Garle M et al. Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels.  Eur J Respir Dis. 1982;  63 399-409
• 36 Van den Berg W, Fokkens J, Lefering J G et al. Tremor measurement in asthma. II. Changes after terbutaline administration suggesting beta-adrenergic blockade.  Eur J Respir Dis. 1982;  63 392-398
• 37 Thiringer G, Svedmyr N. Comparison of infused and inhaled terbutaline in patients with asthma.  Scand J Respir Dis. 1976;  57 17-24
• 38 Bateman D N, Bevan P, Longley B P et al. Cimetidine induced postural and action tremor.  J Neurol Neurosurg Psychiatry. 1981;  44 94
• 39 Patchell R A. Neurological complications of organ transplantation.  Ann Neurol. 1994;  36 688-703
• 40 Wijdicks E F, Wiesner R H, Krom R A. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression.  Neurology. 1995;  45 1962-1964
• 41 David-Neto E, Lemos F B, Furusawa E A et al. Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation.  J Am Soc Nephrol. 2000;  11 343-349
• 42 Kahan B D. Cyclosporine.  N Engl J Med. 1989;  321 1725-1738
• 43 Pirsch J D, Miller J, Deierhoi M H et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation.  Transplantation. 1997;  63 978-983
• 44 Walker R W, Rochstein J A. Neurologic complications of immunosuppressant agents.  Neurol Clin. 1988;  6 261-278
• 45 O’Sullivan D P. Convulsions associated with cyclosporin A.  BMJ. 1985;  290 858
• 46 Erer B, Polchi P, Lucarelli G et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.  Bone Marrow Transplant. 1996;  18 157-162
• 47 Thompson C B, June C H, Sullivan K M et al. Association between cyclosporin neurotoxicity and hypomagnesaemia.  Lancet. 1984;  17 1116-1120
• 48 Wijdicks E F, Dahlke L J, Wiesner R H. Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients.  Neurology. 1999;  52 1708-1710
• 49 Neu A M, Furth S L, Case B W et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506).  Clin Transplant. 1997;  11 412-414
• 50 Trocha K, Winkler M, Haas J et al. Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin.  Transpl Int. 1994;  7 (Suppl 1) S43-S49
• 51 Wijdicks E F, Wiesner R H, Dahlke et al. FK506-induced neurotoxicity in liver transplantation.  Ann Neurol. 1994;  35 498-501
• 52 Neuhaus P, McMaster P, Calne R et al. Neurological complications in the european multicentre study of FK 506 and cyclosporin in primary liver transplantation.  Transpl Int. 1994;  7 (Suppl 1) S27-S31
• 53 Mayer A D, Dmitrewski J, Squifflet J P et al. Multicenter randomised trial comparing tacrolimus (FK605) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.  Transplantation. 1997;  64 436-443
• 54 Plosker G L, Foster R H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.  Drugs. 2000;  59 323-389
• 55 Morgan J C, Kapil D S. Drug-induced tremors.  Lancet Neurol. 2005;  4 866-876
• 56 Gelenberg A J, Jefferson J W. Lithium tremor.  J Clin Psychiatry. 1995;  56 283-287
• 57 Lapierre Y D. Control of lithium tremor with propranolol.  Can Med Assoc J. 1976;  114 619-620
• 58 Pullinger S, Tyrer P. Acute lithium-induced tremor.  Br J Psychiatry. 1983;  143 40-41
• 59 Dave M. Treatment of lithium induced tremor with atenolol.  Can J Psychiatry. 1989;  34 132-133
• 60 Gaby N S, Lefkowitz D S, Israel J R. Treatment of lithium tremor with metropolol.  Am J Psychiatry. 1983;  140 593-595
• 61 Floru L, Tegler J, Wolmsen H. Treatment of lithium tremor with the beta receptor blocker, pindolol.  Int Pharmacopsychiatry. 1979;  14 149-157
• 62 Zaninelli R, Bauer M, Jobert M et al. Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline.  J Clin Psychopharmacol. 2001;  21 190-198
• 63 Rapoport A, Stein D, Shamir E et al. Clinico-tremorgraphic features of neuroleptic-induced tremor.  Int Clin Psychopharmacol. 1998;  13 115-120
• 64 Stacy M, Jankovic J. Tardive tremor.  Mov Disord. 1992;  7 53-57
• 65 Rittmannsberger H. Asterixis induced by psychotropic drug treatment.  Clin Neuropharmacol. 1996;  19 349-355
• 66 Rittmannsberger H, Leblhuber F. Drug-induced asterixis.  Dtsch Med Wochenschr. 1994;  119 585-588
• 67 Boshes R A, Oepen G, Handren M. Flapping tremor produced by high-potency neuroleptics.  J Clin Psychopharmacol. 1991;  11 76-77
• 68 Metzer W S, Paige S R, Newton J E. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor.  Mov Disord. 1993;  8 43-46
• 69 Chaturvedi S K. Metoprolol in the treatment of neuroleptic-induced tremor: case report.  J Clin Psychiatry. 1987;  48 378
• 70 Kulik A V, Wilbur R. Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor.  Prog Neuropsychopharmacol Biol Psychiatry. 1983;  7 223-225
• 71 Safferman A Z, Kane J M, Aronowitz J S et al. The use of clozapine in neurologic disorders.  J Clin Psychiatry. 1994;  55 (Suppl b) 98-101
• 72 Delecluse F, Elogesi J A, Gerard J M. A case of tardive tremor successfully treated with clozapine.  Mov Disord. 1998;  13 846-847
• 73 Koller W, Orebaugh C, Lawson L et al. Pindolol-induced tremor.  Clin Neuropharmacol. 1987;  10 449-452
• 74 Sundberg S, Tiihonen K, Gordin A. Vasodilatory effects of carvediol and pindolol.  J Cardiovasc Pharmacol. 1987;  10 (Suppl 11) 76-80
• 75 Podrid P J, Lown B. Pindolol for ventricular arrhythmia.  Am Heart J. 1982;  104 491-496
• 76 Hod H, Har-Zahav J, Kaplinsky N et al. Pindolol-induced tremor.  Postgrad Med J. 1980;  56 346-347
• 77 Teravainen H, Larsen A, Fogelholm R. Comparison between the effects of pindolol and propranolol on essential tremor.  Neurology. 1977;  27 439-442
• 78 Bartel P R, Ubbink J B, Delport R et al. Vitamin B-6 supplementation and theophylline-related effects in humans.  Am J Clin Nutr. 1994;  60 93-99
• 79 Melamed J, Beaucher W N. Minor symptoms are not predictive of elevated theophylline levels in adults on chronic therapy.  Ann Allergy Asthma Immunol. 1995;  75 516-520
• 80 Bender B, Milgrom H. Theophylline-induced behavior change in children. An objective evaluation of parent’s perceptions.  JAMA. 1992;  267 2621-2624
• 81 Hyman N M, Dennis P D, Sinclair K G. Tremor due to sodium valproate.  Neurology. 1979;  29 1177-1180
• 82 Bruni J, Wilder B J. Valproic acid. Review of a new antiepileptic drug.  Arch Neurol. 1979;  36 393-398
• 83 Despland P A. Tolerance to and unwanted effects of valproate sodium.  Schweiz Rundsch Med Prax. 1994;  83 1132-1139
• 84 Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study.  Cephalgia. 1997;  17 103-108
• 85 Karas B J, Wilder B J, Hammond E J et al. Valproate tremors.  Neurology. 1982;  32 428-432
• 86 Lancman M E, Asconape J J, Walker F. Acetazolamide appears effective in the management of valproate-induced tremor.  Mov Disord. 1994;  9 369
• 87 Karas B J, Wilder B J, Hammond E J et al. Treatment of valproate tremors.  Neurology. 1983;  33 1380-1382